The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R&D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)/Investigational Device Exemption (IDE) enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R&D throughout the award.
Clinical trials are not accepted under this FOA.
Companion FOAs:
Deadlines:
PAR-20-129 Expiration Date New Date April 06, 2023 per issuance of NOT-OD-22-086. (Original Expiration Date: April 6, 2022)
Only United States small business concerns (SBCs) that have had an active NIH SBIR or STTR Phase II or Phase IIB contract or grant award from NIH within the last 36 months are eligible to submit applications for this opportunity. Only one CRP is allowed per Phase II or Phase IIB project. SBCs with currently active and newly awarded Phase II or Phase IIB awards from one of the participating ICs are also eligible.
